Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Tvardi Therapeutics Inc., 3 years.
Tvardi Therapeutics Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 18, 2025 | Seres Therapeutics Inc. | Open-market sale | −4,416 | $0.81 | $3,577 |
| Feb 15, 2025 | Seres Therapeutics Inc. | Option exercise | +2,969 | — | — |
| Feb 15, 2025 | Seres Therapeutics Inc. | Option exercise | +8,907 | — | — |
| Nov 18, 2024 | Seres Therapeutics Inc. | Open-market sale | −977 | $0.54 | $528 |
| Nov 15, 2024 | Seres Therapeutics Inc. | Option exercise | +2,969 | — | — |
| Oct 28, 2024 | Seres Therapeutics Inc. | Open-market sale | −4,334 | $0.69 | $2,990 |
| Oct 27, 2024 | Seres Therapeutics Inc. | Option exercise | +13,744 | — | — |
| Aug 16, 2024 | Seres Therapeutics Inc. | Open-market sale | −973 | $0.84 | $817 |
| Aug 15, 2024 | Seres Therapeutics Inc. | Option exercise | +2,969 | — | — |
| Jun 4, 2024 | Tvardi Therapeutics Inc. | Grant or award | +150,647 | — | — |
| May 15, 2024 | Seres Therapeutics Inc. | Option exercise | +2,968 | — | — |
| May 15, 2024 | Seres Therapeutics Inc. | Open-market sale | −939 | $0.94 | $883 |
| Feb 16, 2024 | Seres Therapeutics Inc. | Open-market sale | −4,400 | $1.08 | $4,752 |
| Feb 15, 2024 | Seres Therapeutics Inc. | Option exercise | +11,875 | — | — |
| Oct 30, 2023 | Seres Therapeutics Inc. | Open-market sale | −4,232 | $1.35 | $5,713 |
Questions about Moltke Lisa Von
What boards is Moltke Lisa Von on?
Moltke Lisa Von sits on the board of Tvardi Therapeutics Inc.
How long has Moltke Lisa Von served on boards?
Our records show at least 4 years of board service across 1 board, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.